Direct-to-patient wearable ECG test to expedite arrhythmia diagnosis launched
Cardiac Insight, a digital healthcare company specializing in wearable technology and automated ECG analysis, announced it launched a direct-to-patient wearable ECG test kit to help address the telehealth demands prompted by the COVID-19 pandemic.
According to a press release from the company, the kit (Heart@Home, Cardiac Insight) will allow physicians to prescribe arrhythmia diagnosis technology (Cardea SOLO Sensor, Cardiac Insight) and instructions for use that can then be shipped directly from the company to the patient’s home.
After the patient has worn the sensor for the prescribed period, they mail the single-use sensor to their cardiologist’s office, at which point clinicians can retrieve data from the device to inform their arrhythmia diagnoses. According to the release, the process takes less than 5 minutes to produce a complete ECG report.
“In these unprecedented times, while legacy ECG service companies employing decades-old technology are scaling back operations and decreasing services, Cardiac Insight is innovating and acting quickly to provide cardiologists and their patients with essential and easy-to-use telehealth options. As a single-use sensor, Cardea SOLO affords patients, doctors and clinical staff more infection control protections with no need for cleaning or transferring devices between patients,” Robert Odell, president and chief operating officer of Cardiac Insight, said in the release. “We believe the new Heart@Home program further strengthens the physician and patient relationship in a time when trust and privacy is more critical than ever, by fostering direct interactions and removing third-party data analysis vendors from the equation.”
Disclosures: Odell is an employee of Cardiac Insight.
Collapse
Read more about